Antiviral therapies: Focus on hepatitis B reverse transcriptase

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 7, 2012, Pages 1060-1071

  Michailidis, Eleftherios ^a   Kirby, Karen A ^a   Hachiya, Atsuko ^a   Yoo, Wangdon ^b   Hong, Sun Pyo ^b   Kim, Soo Ok ^b   Folk, William R ^a   Sarafianos, Stefan G ^a  

^a University of Missouri   (United States)

^b GeneMatrix Inc   (South Korea)

Author keywords

Antivirals; Drug resistance; Genotype; HBV; NRTIs

Indexed keywords

ADEFOVIR; AMINO ACID; DEOXYCYTIDINE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; VALTORCITABINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DRUG APPROVAL; DRUG BINDING; DRUG SENSITIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENOMICS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 84861235025     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.04.006     Document Type: Review

References (142)

1. S.W. Aberle, J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, and E. Puchhammer-Stockl Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions J Clin Microbiol 39 2001 1972 1974
2. S.H. Ahn, Y. Kim do, H.Y. Chang, S.P. Hong, J.S. Shin, and Y.S. Kim Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea J Med Virol 78 2006 1564 1571
3. N. Akuta, F. Suzuki, M. Kobayashi, A. Tsubota, Y. Suzuki, and T. Hosaka The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment J Hepatol 38 2003 315 321
4. S. Amini-Bavil-Olyaee, U. Herbers, S.R. Mohebbi, F. Sabahi, M.R. Zali, and T. Luedde Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome J Hepatol 51 2009 647 654
5. P. Angus, R. Vaughan, S. Xiong, H. Yang, W. Delaney, and C. Gibbs Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology 125 2003 292 297
6. Y.J. Bai, J.R. Zhao, G.T. Lv, W.H. Zhang, Y. Wang, and X.J. Yan Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization World J Gastroenterol 9 2003 2344 2347
7. C.J. Baldick, D.J. Tenney, C.E. Mazzucco, B.J. Eggers, R.E. Rose, and K.A. Pokornowski Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance Hepatology 47 2008 1473 1482
8. A. Bartholomeusz, and S. Locarnini Hepatitis B virus mutations associated with antiviral therapy J Med Virol 78 Suppl 1 2006 S52 S55
9. A. Bartholomeusz, B.G. Tehan, and D.K. Chalmers Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations Antivir Ther 9 2004 149 160
10. M.M. Bartholomew, R.W. Jansen, L.J. Jeffers, K.R. Reddy, L.C. Johnson, and H. Bunzendahl Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation Lancet 349 1997 20 22
11. Y. Benhamou, M. Bochet, V. Thibault, V. Calvez, M.H. Fievet, and P. Vig Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study Lancet 358 2001 718 723
12. D. Bhattacharya, and C.L. Thio Review of hepatitis B therapeutics Clin Infect Dis 51 2010 1201 1208
13. G. Billioud, C. Pichoud, R. Parent, and F. Zoulim Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants J Hepatol 2012
14. K. Borroto-Esoda, M.D. Miller, and S. Arterburn Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials J Hepatol 47 2007 492 498
15. A.M. Bozdayi, O. Uzunalimoglu, A.R. Turkyilmaz, N. Aslan, O. Sezgin, and T. Sahin YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine J Viral Hepat 10 2003 256 265
16. P.A. Cane, P. Cook, D. Ratcliffe, D. Mutimer, and D. Pillay Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus Antimicrob Agents Chemother 43 1999 1600 1608
17. H.L. Chan, V.W. Wong, C.H. Tse, A.M. Chim, H.Y. Chan, and G.L. Wong Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B Aliment Pharmacol Ther 25 2007 891 898
18. T.T. Chang, and C.L. Lai Hepatitis B virus with primary resistance to adefovir N Engl J Med 355 2006 322 323 author reply 323
19. C.H. Chen, C.M. Lee, C.H. Hung, J.H. Wang, T.H. Hu, and C.S. Changchien Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients J Gastroenterol Hepatol 26 2011 461 468
20. R.N. Chien, C.T. Yeh, S.L. Tsai, C.M. Chu, and Y.F. Liaw Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 2003 1267 1273
21. Y. Chong, L. Stuyver, M.J. Otto, R.F. Schinazi, and C.K. Chu Mechanism of antiviral activities of 3′-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach Antivir Chem Chemother 14 2003 309 319
22. B. Clarke, and S. Bloor Molecular genotyping of hepatitis B virus J Clin Virol 25 Suppl 3 2002 S41 S45
23. H. Damerow, L. Yuen, J. Wiegand, C. Walker, C.T. Bock, and S. Locarnini Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern J Med Virol 82 2010 1850 1858
24. K. Das, X. Xiong, H. Yang, C.E. Westland, C.S. Gibbs, and S.G. Sarafianos Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J Virol 75 2001 4771 4779
25. E. De Clercq, G. Férir, S. Kaptein, and J. Neyts Antiviral treatment of chronic hepatitis B virus (HBV) infections Viruses 2 2010 1279 1305
26. W.E.t. Delaney, S. Locarnini, and T. Shaw Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation Antivir Chem Chemother 12 2001 1 35
27. W.E.t. Delaney, H. Yang, C.E. Westland, K. Das, E. Arnold, and C.S. Gibbs The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro J Virol 77 2003 11833 11841
28. C. Delaugerre, A.G. Marcelin, V. Thibault, G. Peytavin, T. Bombled, and M.V. Bochet Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine Antimicrob Agents Chemother 46 2002 1586 1588
29. M. Devesa, C. Rodriguez, G. Leon, F. Liprandi, and F.H. Pujol Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes J Med Virol 72 2004 377 384
30. T.E. de Vries-Sluijs, J.G. Reijnders, B.E. Hansen, H.L. Zaaijer, J.M. Prins, and S.D. Pas Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus Gastroenterology 139 2010 1934 1941
31. J.L. Dienstag Hepatitis B virus infection N Engl J Med 359 2008 1486 1500
32. J.L. Dienstag, R.P. Perrillo, E.R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1995 1657 1661
33. J.L. Dienstag, E.R. Schiff, T.L. Wright, R.P. Perrillo, H.W. Hann, and Z. Goodman Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1999 1256 1263
34. A. Erhardt, U. Reineke, D. Blondin, W.H. Gerlich, O. Adams, and T. Heintges Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B Hepatology 31 2000 716 725
35. A. Foli, K.M. Sogocio, B. Anderson, M. Kavlick, M.W. Saville, and M.A. Wainberg In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2- (phosphonomethoxy)ethyl]adenine (PMEA) Antiviral Res 32 1996 91 98
36. S.K. Fung, H.B. Chae, R.J. Fontana, H. Conjeevaram, J. Marrero, and K. Oberhelman Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 2006 283 290
37. S.K. Fung, F. Wong, M. Hussain, and A.S. Lok Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B J Viral Hepat 11 2004 432 438
38. M. Ghany, and T.J. Liang Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B Gastroenterology 132 2007 1574 1585
39. R. Gish, J.D. Jia, S. Locarnini, and F. Zoulim Selection of chronic hepatitis B therapy with high barrier to resistance Lancet Infect Dis 2012
40. J.G. Hall, P.S. Eis, S.M. Law, L.P. Reynaldo, J.R. Prudent, and D.J. Marshall Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction Proc Natl Acad Sci USA 97 2000 8272 8277
41. K.H. Han, S.P. Hong, S.H. Choi, S.K. Shin, S.W. Cho, and S.H. Ahn Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B Antivir Ther 16 2011 77 87
42. S.P. Hong, N.K. Kim, S.G. Hwang, H.J. Chung, S. Kim, and J.H. Han Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments J Hepatol 40 2004 837 844
43. S.P. Hong, S.K. Shin, E.H. Lee, E.O. Kim, S.I. Ji, and H.J. Chung High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry Nat Protoc 3 2008 1476 1484
44. J. Hou, R. Schilling, H.L. Janssen, B.E. Hansen, R. Heijtink, and E. Sablon Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance J Med Virol 79 2007 1055 1063
45. T.H. Hsieh, T.C. Tseng, C.J. Liu, M.Y. Lai, P.J. Chen, and H.L. Hsieh Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C Antivir Ther 14 2009 1157 1163
46. J. Inoue, Y. Ueno, Y. Wakui, H. Niitsuma, K. Fukushima, and Y. Yamagiwa Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern J Viral Hepat 18 2011 206 215
47. M.K. Jain, L. Comanor, C. White, P. Kipnis, C. Elkin, and K. Leung Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response J Viral Hepat 14 2007 176 182
48. M.K. Jain, and C.L. Zoellner Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naive patient treated for chronic HBV AIDS 21 2007 2365 2366
49. H.L. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, and Y. Cakaloglu Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
50. S. Kamili, V. Sozzi, G. Thompson, K. Campbell, C.M. Walker, and S. Locarnini Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model Hepatology 49 2009 1483 1491
51. J.H. Kao, C.J. Liu, and D.S. Chen Hepatitis B viral genotypes and lamivudine resistance J Hepatol 36 2002 303 304
52. J.H. Kao, N.H. Wu, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 2000 998 1002
53. A. Kay, and F. Zoulim Hepatitis B virus genetic variability and evolution Virus Res 127 2007 164 176
54. H.S. Kim, K.H. Han, S.H. Ahn, E.O. Kim, H.Y. Chang, and M.S. Moon Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization Antivir Ther 10 2005 441 449
55. Y.J. Kim, S.O. Kim, H.J. Chung, M.S. Jee, B.G. Kim, and K.M. Kim Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments Clin Chem 51 2005 1123 1131
56. H. Kumada Continued lamivudine therapy in patients with chronic hepatitis B Intervirology 46 2003 377 387
57. K. Lacombe, A. Ollivet, J. Gozlan, S. Durantel, N. Tran, and P.M. Girard A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient AIDS 20 2006 2229 2231
58. C.L. Lai, R.N. Chien, N.W. Leung, T.T. Chang, R. Guan, and D.I. Tai A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 339 1998 61 68
59. D.R. Langley, A.W. Walsh, C.J. Baldick, B.J. Eggers, R.E. Rose, and S.M. Levine Inhibition of hepatitis B virus polymerase by entecavir J Virol 81 2007 3992 4001
60. G.L. Le Bouvier, R.W. McCollum, W.J. Hierholzer Jr., G.R. Irwin, S. Krugman, and J.P. Giles Subtypes of Australia antigen and hepatitis-B virus J Am Med Assoc 222 1972 928 930
61. C.H. Lee, S.O. Kim, K.S. Byun, M.S. Moon, E.O. Kim, and J.E. Yeon Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough Gastroenterology 130 2006 1144 1152
62. Y.S. Lee, Y.H. Chung, J.A. Kim, S.E. Kim, J.W. Shin, and K.M. Kim Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy Liver Int 29 2009 552 556
63. Y.S. Lee, D.J. Suh, Y.S. Lim, S.W. Jung, K.M. Kim, and H.C. Lee Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy Hepatology 43 2006 1385 1391
64. Y.F. Liaw, E. Gane, N. Leung, S. Zeuzem, Y. Wang, and C.L. Lai 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B Gastroenterology 136 2009 486 495
65. Y.F. Liaw, N.W. Leung, T.T. Chang, R. Guan, D.I. Tai, and K.Y. Ng Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 119 2000 172 180
66. C.L. Lin, and J.H. Kao The clinical implications of hepatitis B virus genotype: recent advances J Gastroenterol Hepatol 26 Suppl 1 2011 123 130
67. R. Ling, D. Mutimer, M. Ahmed, E.H. Boxall, E. Elias, and G.M. Dusheiko Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine Hepatology 24 1996 711 713
68. S. Litwin, E. Toll, A.R. Jilbert, and W.S. Mason The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations J Clin Virol 34 Suppl 1 2005 S96 S107
69. B.M. Liu, T. Li, J. Xu, X.G. Li, J.P. Dong, and P. Yan Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients Antiviral Res 85 2010 512 519
70. C.J. Liu, J.H. Kao, P.J. Chen, T.C. Chen, F.Y. Lin, and M.Y. Lai Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants J Viral Hepat 13 2006 387 395
71. C.J. Liu, J.H. Kao, P.J. Chen, M.Y. Lai, and D.S. Chen Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan J Biomed Sci 9 2002 166 170
72. H. Liu, R. Mao, L. Fan, J. Xia, Y. Li, and Y. Yin Detection of lamivudine- or adefovir-resistant hepatitis B virus mutations by a liquid array J Virol Methods 175 2011 1 6
73. X. Liu, and R.F. Schinazi Hepatitis B virus resistance to lamivudine and its clinical implications Antivir Chem Chemother 13 2002 143 155
74. S. Locarnini, and W.S. Mason Cellular and virological mechanisms of HBV drug resistance J Hepatol 44 2006 422 431
75. S.A. Locarnini, and L. Yuen Molecular genesis of drug-resistant and vaccine-escape HBV mutants Antivir Ther 15 2010 451 461
76. A.S. Lok, C.L. Lai, N. Leung, G.B. Yao, Z.Y. Cui, and E.R. Schiff Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 2003 1714 1722
77. A.S. Lok, F. Zoulim, S. Locarnini, A. Bartholomeusz, M.G. Ghany, and J.M. Pawlotsky Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 2007 254 265
78. M.A. McMahon, B.L. Jilek, T.P. Brennan, L. Shen, Y. Zhou, and M. Wind-Rotolo The HBV drug entecavir - effects on HIV-1 replication and resistance N Engl J Med 356 2007 2614 2621
79. E. Michailidis, K. Singh, K.A. Kirby, A. Hachiya, W. Yoo, and S.P. Hong Hepatitis B virus genotypic differences map structurally close to NRTI resistance hot spots Int J Curr Chem 2 2011 253 260
80. R.H. Miller, S. Kaneko, C.T. Chung, R. Girones, and R.H. Purcell Compact organization of the hepatitis B virus genome Hepatology 9 1989 322 327
81. F. Mitsui, M. Tsuge, T. Kimura, S. Kitamura, H. Abe, and H. Saneto Importance of serum concentration of adefovir for lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B Antimicrob Agents Chemother 54 2010 3205 3211
82. H. Mitsuya, R.F. Jarrett, M. Matsukura, F. Di Marzo Veronese, A.L. DeVico, and M.G. Sarngadharan Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2′,3′- dideoxynucleosides in vitro Proc Natl Acad Sci USA 84 1987 2033 2037
83. M. Mizokami, E. Orito, K. Ohba, K. Ikeo, J.Y. Lau, and T. Gojobori Constrained evolution with respect to gene overlap of hepatitis B virus J Mol Evol 44 Suppl 1 1997 S83 S90
84. M. Mukaide, Y. Tanaka, I.T. Shin, M.F. Yuen, F. Kurbanov, and O. Yokosuka Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation Antimicrob Agents Chemother 54 2010 882 889
85. K.K. Murray DNA sequencing by mass spectrometry J Mass Spectrom 31 1996 1203 1215
86. M. Nelson, S. Portsmouth, J. Stebbing, M. Atkins, A. Barr, and G. Matthews An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals AIDS 17 2003 F7 F10
87. H. Norder, A.M. Courouce, P. Coursaget, J.M. Echevarria, S.D. Lee, and I.K. Mushahwar Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes Intervirology 47 2004 289 309
88. H. Norder, A.M. Courouce, and L.O. Magnius Molecular basis of hepatitis B virus serotype variations within the four major subtypes J Gen Virol 73 Pt 12 1992 3141 3145
89. H. Norder, A.M. Courouce, and L.O. Magnius Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes Virology 198 1994 489 503
90. H. Norder, B. Hammas, S. Lofdahl, A.M. Courouce, and L.O. Magnius Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains J Gen Virol 73 Pt 5 1992 1201 1208
91. N. Ogata, K. Fujii, S. Takigawa, M. Nomoto, T. Ichida, and H. Asakura Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in japanese patients with chronic hepatitis B J Med Virol 59 1999 270 276
92. K. Ohba, M. Mizokami, T. Ohno, K. Suzuki, E. Orito, and J.Y. Lau Relationships between serotypes and genotypes of hepatitis B virus: genetic classification of HBV by use of surface genes Virus Res 39 1995 25 34
93. H. Okamoto, F. Tsuda, H. Sakugawa, R.I. Sastrosoewignjo, M. Imai, and Y. Miyakawa Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes J Gen Virol 69 Pt 10 1988 2575 2583
94. S.K. Ono, N. Kato, Y. Shiratori, J. Kato, T. Goto, and R.F. Schinazi The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance J Clin Invest 107 2001 449 455
95. C. Osiowy, J.P. Villeneuve, E.J. Heathcote, E. Giles, and J. Borlang Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2) J Clin Microbiol 44 2006 1994 1997
96. Y.H. Paik, K.H. Han, S.P. Hong, H.W. Lee, K.S. Lee, and S.O. Kim The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B Antivir Ther 11 2006 447 455
97. J.M. Pawlotsky, G. Dusheiko, A. Hatzakis, D. Lau, G. Lau, and T.J. Liang Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach Gastroenterology 134 2008 405 415
98. R. Perrillo Benefits and risks of interferon therapy for hepatitis B Hepatology 49 2009 S103 S111
99. S.Y. Rhee, S. Margeridon-Thermet, M.H. Nguyen, T.F. Liu, R.M. Kagan, and B. Beggel Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery Antiviral Res 88 2010 269 275
100. E. Sablon, and F. Shapiro Advances in molecular diagnosis of HBV infection and drug resistance Int J Med Sci 2 2005 8 16
101. S.G. Sarafianos, A.D. Clark Jr., K. Das, S. Tuske, J.J. Birktoft, and P. Ilankumaran Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA EMBO J 21 2002 6614 6624
102. S.G. Sarafianos, K. Das, A.D. Clark Jr., J. Ding, P.L. Boyer, and S.H. Hughes Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids Proc Natl Acad Sci USA 96 1999 10027 10032
103. S.G. Sarafianos, B. Marchand, K. Das, D.M. Himmel, M.A. Parniak, and S.H. Hughes Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition J Mol Biol 385 2009 693 713
104. S. Schaefer Hepatitis B virus taxonomy and hepatitis B virus genotypes World J Gastroenterol 13 2007 14 21
105. O. Schildgen, H. Sirma, A. Funk, C. Olotu, U.C. Wend, and H. Hartmann Variant of hepatitis B virus with primary resistance to adefovir N Engl J Med 354 2006 1807 1812
106. M. Seifer, R.K. Hamatake, R.J. Colonno, and D.N. Standring In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir Antimicrob Agents Chemother 42 1998 3200 3208
107. M. Seifer, A. Patty, I. Serra, B. Li, and D.N. Standring Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir Antiviral Res 81 2009 147 155
108. T. Shaw, A. Bartholomeusz, and S. Locarnini HBV drug resistance: mechanisms, detection and interpretation J Hepatol 44 2006 593 606
109. J. Sheldon, B. Ramos, J. Garcia-Samaniego, P. Rios, A. Bartholomeusz, and M. Romero Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity J Acquir Immune Defic Syndr 46 2007 279 282
110. S. Shiina, H. Fujino, Y. Uta, K. Tagawa, T. Unuma, and M. Yoneyama Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I. Analysis of 1744 HBsAg carriers Am J Gastroenterol 86 1991 866 871
111. Y. Song, E. Dai, J. Wang, H. Liu, J. Zhai, and C. Chen Genotyping of hepatitis B virus (HBV) by oligonucleotides microarray Mol Cell Probes 20 2006 121 127
112. V. Soriano, P. Barreiro, and M. Nunez Management of chronic hepatitis B and C in HIV-coinfected patients J Antimicrob Chemother 57 2006 815 818
113. L. Stuyver, S. De Gendt, C. Van Geyt, F. Zoulim, M. Fried, and R.F. Schinazi A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness J Gen Virol 81 2000 67 74
114. L. Stuyver, C. Van Geyt, S. De Gendt, G. Van Reybroeck, F. Zoulim, and G. Leroux-Roels Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy J Clin Microbiol 38 2000 702 707
115. L.J. Stuyver, S.A. Locarnini, A. Lok, D.D. Richman, W.F. Carman, and J.L. Dienstag Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region Hepatology 33 2001 751 757
116. F. Sugauchi, H. Kumada, S.A. Acharya, S.M. Shrestha, M.T. Gamutan, and M. Khan Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A J Gen Virol 85 2004 811 820
117. V. Svicher, V. Cento, R. Salpini, F. Mercurio, M. Fraune, and B. Beggel Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development Dig Liver Dis 43 2011 975 983
118. K. Tadokoro, M. Kobayashi, T. Yamaguchi, F. Suzuki, S. Miyauchi, and T. Egashira Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes J Virol Methods 138 2006 30 39
119. E.P. Tchesnokov, A. Obikhod, R.F. Schinazi, and M. Gotte Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase J Biol Chem 283 2008 34218 34228
120. D.J. Tenney, S.M. Levine, R.E. Rose, A.W. Walsh, S.P. Weinheimer, and L. Discotto Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 2004 3498 3507
121. D.J. Tenney, R.E. Rose, C.J. Baldick, S.M. Levine, K.A. Pokornowski, and A.W. Walsh Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present Antimicrob Agents Chemother 51 2007 902 911
122. D.J. Tenney, R.E. Rose, C.J. Baldick, K.A. Pokornowski, B.J. Eggers, and J. Fang Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
123. C.G. Teo, and S.A. Locarnini Potential threat of drug-resistant and vaccine-escape HBV mutants to public health Antivir Ther 15 2010 445 449
124. J. Torresi The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus J Clin Virol 25 2002 97 106
125. J. Torresi, L. Earnest-Silveira, G. Deliyannis, K. Edgtton, H. Zhuang, and S.A. Locarnini Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy Virology 293 2002 305 313
126. J.P. Villeneuve, D. Durantel, S. Durantel, C. Westland, S. Xiong, and C.L. Brosgart Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient J Hepatol 39 2003 1085 1089
127. S. Villet, G. Billioud, C. Pichoud, J. Lucifora, O. Hantz, and C. Sureau In vitro characterization of viral fitness of therapy-resistant hepatitis B variants Gastroenterology 136 2009 168 176 e162
128. C.T. Wai, C.J. Chu, M. Hussain, and A.S. Lok HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C Hepatology 36 2002 1425 1430
129. C. Westland, W.t. Delaney, H. Yang, S.S. Chen, P. Marcellin, and S. Hadziyannis Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1 Gastroenterology 125 2003 107 116
130. C.E. Westland, H. Yang, W.E.t. Delaney, C.S. Gibbs, M.D. Miller, and M. Wulfsohn Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B Hepatology 38 2003 96 103
131. C.E. Westland, H. Yang, W.E.t. Delaney, M. Wulfsohn, N. Lama, and C.S. Gibbs Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients J Viral Hepat 12 2005 67 73
132. S.A. Whalley, D. Brown, C.G. Teo, G.M. Dusheiko, and N.A. Saunders Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler J Clin Microbiol 39 2001 1456 1459
133. C.T. Yeh, R.N. Chien, C.M. Chu, and Y.F. Liaw Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy Hepatology 31 2000 1318 1326
134. J.E. Yeon, W. Yoo, S.P. Hong, Y.J. Chang, S.K. Yu, and J.H. Kim Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil Gut 55 2006 1488 1495
135. H.J. Yim, M. Hussain, Y. Liu, S.N. Wong, S.K. Fung, and A.S. Lok Evolution of multi-drug resistant hepatitis B virus during sequential therapy Hepatology 44 2006 703 712
136. R. Zhang, Y. Deng, C.P. Muller, Z.Y. Ou, L. Ma, and M. Wang Determination of hepatitis B virus genotype by flow-through reverse dot blot J Clin Virol 39 2007 94 100
137. X. Zhang, F. Zoulim, F. Habersetzer, S. Xiong, and C. Trepo Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B J Med Virol 48 1996 8 16
138. Y. Zhong, J. Lv, J. Li, X. Xing, H. Zhu, and H. Su Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B Antiviral Res 93 2012 185 190
139. Y. Zhu, M. Curtis, X. Qi, M.D. Miller, and K. Borroto-Esoda Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues Antivir Chem Chemother 19 2009 165 176
140. B. Zollner, J. Petersen, E. Puchhammer-Stockl, J. Kletzmayr, M. Sterneck, and L. Fischer Viral features of lamivudine resistant hepatitis B genotypes A and D Hepatology 39 2004 42 50
141. F. Zoulim Assessing hepatitis B virus resistance in vitro and molecular mechanisms of nucleoside resistance Semin Liver Dis 22 Suppl 1 2002 23 31
142. F. Zoulim, and S. Locarnini Management of treatment failure in chronic hepatitis B J Hepatol 56 Suppl 1 2012 S112 S122